Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of ABBV-932 with Itraconazole in Bipolar Disorder
NCT07071532Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ABBV-932 in bipolar disorder (BD), sponsored by AbbVie Inc. Primary endpoints: Maximum Plasma Concentration up to 29 days, Time to Maximum Plasma Concentration up to 29 days and 6 more. Started Aug 2026; status: recruiting.
02
Drugs
ABBV-932
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT07071532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07071532.